Soghra Hesam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Soghra Hesam has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Haghparast
Neuroscience Research Center, Institute of Neuroscience and Cognition, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Ghassem Attarzadeh-Yazdi
Molecular Medicine Research Centre, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2 shared publications - Hamid Sepehri
Neuroscience Research Center, Biomedical Research Institute, Golestan University of Medical Sciences, Gorgan, Iran
2 shared publications Pegah Azizi
Neuroscience Research Center, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, P.O. Box 19615-1178, Tehran, Iran
2 shared publications- Saeid Yazdi-Ravandi
Behavioral Disorders and Substance Abuse Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
2 shared publications Sara Karimi
Molecular Medicine Research Centre, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2 shared publications
Latest Publications
- Open Access
- 1 June 2025
- Published by InkVista Publishing House
- Vol. 9 (2) , 14-16
Investigation of the effects of lipopolysaccharide preconditioning on neuropathic pain induced by chronic sciatic nerve constriction injury in rats
Background: Neuropathic pain results from nerve injury and involves pro-inflammatory cytokines that activate pain-sensing neurons, contributing to both the onset and maintenance of pain. This study investigated the effect of lipopolysaccharide (LPS) preconditioning on pain following sciatic nerve constriction in rats. Methods: Neuropathic pain was induced via the chronic constriction ...
- 1 June 2025
- Published by InkVista Publishing House
- Vol. 9 (2) , 14-16
Open AccessInvestigation of the effects of lipopolysaccharide preconditioning on neuropathic pain induced by chronic sciatic nerve constriction injury in rats
Background: Neuropathic pain results from nerve injury and involves pro-inflammatory cytokines that activate pain-sensing neurons, contributing to both the onset and maintenance of pain. This study investigated the effect of lipopolysaccharide (LPS) preconditioning on pain following sciatic nerve constriction in rats. Methods: Neuropathic pain was induced via the chronic constriction ...
- Open Access
- 1 February 2024
- Published by Apex Publishing in Journal of Clinical and Basic Research
- Vol. 8 (1) , 16-18
Prevalence of Post-traumatic epilepsy in epilepsy patients referred to Sayad Shirazi hospital in Gorgan from 2018 to 2021
Background: Traumatic brain injury (TBI) is a significant medical concern, with post-traumatic epilepsy (PTE) being one of its consequences. Epilepsy, with a global prevalence of 1%, is the third most common neurological disorder after stroke and Alzheimer’s disease. Trauma accounts for 20% of symptomatic epilepsy cases. Understanding the prevalence of PTE and ...
- 1 February 2024
- Published by Apex Publishing in Journal of Clinical and Basic Research
- Vol. 8 (1) , 16-18
Open AccessPrevalence of Post-traumatic epilepsy in epilepsy patients referred to Sayad Shirazi hospital in Gorgan from 2018 to 2021
Background: Traumatic brain injury (TBI) is a significant medical concern, with post-traumatic epilepsy (PTE) being one of its consequences. Epilepsy, with a global prevalence of 1%, is the third most common neurological disorder after stroke and Alzheimer’s disease. Trauma accounts for 20% of symptomatic epilepsy cases. Understanding the prevalence of PTE and ...
- 1 September 2018
- Published by Springer Nature in Neurochemical Research
- Vol. 43 (10) , 1978-1985
Monophosphoryl Lipid A and Pam3Cys Prevent the Increase in Seizure Susceptibility and Epileptogenesis in Rats Undergoing Traumatic Brain Injury
Five percent of all epilepsy cases are attributed to traumatic brain injury (TBI), which are known as post-traumatic epilepsy (PTE). Finding preventive strategies for PTE is valuable. Remarkable feature of TBI is activation of microglia and subsequent neuroinflammation, which provokes epileptogenesis. The toll-like receptor agonists monophosphoryl lipid A (MPL) and tri-palmitoyl-S-glyceryl-cysteine (Pam3Cys) are safe, well-tolerated and effective adjuvants existing in prophylactic human vaccines. We examined the impact of early injection of MPL and Pam3Cys to rats, on the rate of kindled seizures acquisition following TBI. Rats received a single dose (1 µg/rat) of MPL or Pam3Cys through intracerebroventricular injection. 5 days later, trauma was exerted to temporo-parietal cortex of rats by controlled cortical impact device. After 24 h, traumatic rats underwent amygdala kindling. Brain level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) was also measured in traumatic rats by immunoblotting. Compared to non-traumatic (sham-operated) rats, traumatic rats showed three times lower seizure threshold (133 ± 5 µA vs. 416.3 ± 16 µA, p < 0.001); about three times less number of stimuli to become kindled (5 ± 1 vs. 14 ± 2, p < 0.01); longer duration of kindled seizure parameters including entire seizure behavior, generalized seizures, and afterdischarges (p < 0.001); and a two times increase in the TNF-α level. MPL and Pam3Cys did not change kindling rate and the seizure parameters in sham-operated rats. The MPL- and Pam3Cys-pretreated traumatic rats displayed seizure threshold, speed of kindling, and duration of kindled seizure parameters, similar to the non-traumatic rats. Pretreatment by MPL and Pam3Cys prevented the increase in TNF-α level by trauma. Given that MPL and Pam3Cys currently have clinical use as well-tolerated vaccines with reliable safety, they have the potential to be used in prevention of PTE.
- 1 September 2018
- Published by Springer Nature in Neurochemical Research
- Vol. 43 (10) , 1978-1985
Monophosphoryl Lipid A and Pam3Cys Prevent the Increase in Seizure Susceptibility and Epileptogenesis in Rats Undergoing Traumatic Brain Injury
Five percent of all epilepsy cases are attributed to traumatic brain injury (TBI), which are known as post-traumatic epilepsy (PTE). Finding preventive strategies for PTE is valuable. Remarkable feature of TBI is activation of microglia and subsequent neuroinflammation, which provokes epileptogenesis. The toll-like receptor agonists monophosphoryl lipid A (MPL) and tri-palmitoyl-S-glyceryl-cysteine (Pam3Cys) are safe, well-tolerated and effective adjuvants existing in prophylactic human vaccines. We examined the impact of early injection of MPL and Pam3Cys to rats, on the rate of kindled seizures acquisition following TBI. Rats received a single dose (1 µg/rat) of MPL or Pam3Cys through intracerebroventricular injection. 5 days later, trauma was exerted to temporo-parietal cortex of rats by controlled cortical impact device. After 24 h, traumatic rats underwent amygdala kindling. Brain level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) was also measured in traumatic rats by immunoblotting. Compared to non-traumatic (sham-operated) rats, traumatic rats showed three times lower seizure threshold (133 ± 5 µA vs. 416.3 ± 16 µA, p < 0.001); about three times less number of stimuli to become kindled (5 ± 1 vs. 14 ± 2, p < 0.01); longer duration of kindled seizure parameters including entire seizure behavior, generalized seizures, and afterdischarges (p < 0.001); and a two times increase in the TNF-α level. MPL and Pam3Cys did not change kindling rate and the seizure parameters in sham-operated rats. The MPL- and Pam3Cys-pretreated traumatic rats displayed seizure threshold, speed of kindling, and duration of kindled seizure parameters, similar to the non-traumatic rats. Pretreatment by MPL and Pam3Cys prevented the increase in TNF-α level by trauma. Given that MPL and Pam3Cys currently have clinical use as well-tolerated vaccines with reliable safety, they have the potential to be used in prevention of PTE.
- 23 December 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 232 (12) , 2097-2112
Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making
Despite the evidence for altered decision making in cannabis abusers, the role of the cannabinoid system in decision-making circuits has not been studied. Here, we examined the effects of cannabinoid modulation during cost-benefit decision making in the anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC), key brain areas involved in decision making. We trained different groups of rats in a delay-based and an effort-based form of cost-benefit T-maze decision-making task. During test days, the rats received local injections of either vehicle or ACEA, a cannabinoid type-1 receptor (CB1R) agonist in the ACC or OFC. We measured spontaneous locomotor activity following the same treatments and characterized CB1Rs localization on different neuronal populations within these regions using immunohistochemistry. We showed that CB1R activation in the ACC impaired decision making such that rats were less willing to invest physical effort to gain high reward. Similarly, CB1R activation in the OFC induced impulsive pattern of choice such that rats preferred small immediate rewards to large delayed rewards. Control tasks ensured that the effects were specific for differential cost-benefit tasks. Furthermore, we characterized widespread colocalizations of CB1Rs on GABAergic axonal ends but few colocalizations on glutamatergic, dopaminergic, and serotonergic neuronal ends. These results provide first direct evidence that the cannabinoid system plays a critical role in regulating cost-benefit decision making in the ACC and OFC and implicate cannabinoid modulation of synaptic ends of predominantly interneurons and to a lesser degree other neuronal populations in these two frontal regions.
- 23 December 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 232 (12) , 2097-2112
Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making
Despite the evidence for altered decision making in cannabis abusers, the role of the cannabinoid system in decision-making circuits has not been studied. Here, we examined the effects of cannabinoid modulation during cost-benefit decision making in the anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC), key brain areas involved in decision making. We trained different groups of rats in a delay-based and an effort-based form of cost-benefit T-maze decision-making task. During test days, the rats received local injections of either vehicle or ACEA, a cannabinoid type-1 receptor (CB1R) agonist in the ACC or OFC. We measured spontaneous locomotor activity following the same treatments and characterized CB1Rs localization on different neuronal populations within these regions using immunohistochemistry. We showed that CB1R activation in the ACC impaired decision making such that rats were less willing to invest physical effort to gain high reward. Similarly, CB1R activation in the OFC induced impulsive pattern of choice such that rats preferred small immediate rewards to large delayed rewards. Control tasks ensured that the effects were specific for differential cost-benefit tasks. Furthermore, we characterized widespread colocalizations of CB1Rs on GABAergic axonal ends but few colocalizations on glutamatergic, dopaminergic, and serotonergic neuronal ends. These results provide first direct evidence that the cannabinoid system plays a critical role in regulating cost-benefit decision making in the ACC and OFC and implicate cannabinoid modulation of synaptic ends of predominantly interneurons and to a lesser degree other neuronal populations in these two frontal regions.